195 related articles for article (PubMed ID: 29695399)
1. HIF-1α and mTOR - Possible Novel Strategies of Targeted Therapies in p16-positive and -negative HNSCC.
Kramer B; Polit M; Birk R; Rotter N; Aderhold C
Cancer Genomics Proteomics; 2018; 15(3):175-184. PubMed ID: 29695399
[TBL] [Abstract][Full Text] [Related]
2. Impact of Small Molecules on β-Catenin and E-Cadherin Expression in HPV16-positive and -negative Squamous Cell Carcinomas.
Kramer B; Hock C; Schultz JD; Lammert A; Kuhlin B; Birk R; Hörmann K; Aderhold C
Anticancer Res; 2017 Jun; 37(6):2845-2852. PubMed ID: 28551620
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine Kinase Inhibition in HPV-related Squamous Cell Carcinoma Reveals Beneficial Expression of cKIT and Src.
Kramer B; Kneissle M; Birk R; Rotter N; Aderhold C
Anticancer Res; 2018 May; 38(5):2723-2731. PubMed ID: 29715092
[TBL] [Abstract][Full Text] [Related]
4. In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
Secades P; de Santa-María IS; Merlo A; Suarez C; Chiara MD
Head Neck; 2015 Aug; 37(8):1150-62. PubMed ID: 24798801
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
[TBL] [Abstract][Full Text] [Related]
6. Targeted Therapies in HPV-positive and -negative HNSCC - Alteration of EGFR and VEGFR-2 Expression In Vitro.
Kramer B; Hock C; Birk R; Sauter A; Stuck BA; Hörmann K; Schultz JD; Aderhold C
Anticancer Res; 2016 Jun; 36(6):2799-807. PubMed ID: 27272791
[TBL] [Abstract][Full Text] [Related]
7. FGF Expression in HPV16-positive and -negative SCC After Treatment With Small-molecule Tyrosine Kinase Inhibitors and Everolimus.
Huber L; Birk R; Knuettel M; Rotter N; Aderhold C; Scherl C; Lammert A; Jungbauer F; Kramer B
Anticancer Res; 2020 Oct; 40(10):5621-5630. PubMed ID: 32988886
[TBL] [Abstract][Full Text] [Related]
8. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
Aderhold C; Faber A; Umbreit C; Birk R; Weiss C; Sommer JU; Hörmann K; Schultz JD
Anticancer Res; 2015 Apr; 35(4):1951-9. PubMed ID: 25862847
[TBL] [Abstract][Full Text] [Related]
9. Effect of selective small molecule inhibitors on MMP-9 and VEGFR-1 expression in p16-positive and -negative squamous cell carcinoma.
Kramer B; Schultz JD; Hock C; Sauter A; Stuck BA; Hörmann K; Birk R; Aderhold C
Oncol Lett; 2017 May; 13(5):3269-3276. PubMed ID: 28521433
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine Kinase Inhibitors and Everolimus Reduce IGF1R Expression in HPV16-positive and -negative Squamous Cell Carcinoma.
Kramer B; Schell A; Aderhold C; Huber L; Mueller CE; Rotter N; Birk R
Anticancer Res; 2020 Jul; 40(7):3847-3855. PubMed ID: 32620624
[TBL] [Abstract][Full Text] [Related]
11. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms.
Pore N; Jiang Z; Gupta A; Cerniglia G; Kao GD; Maity A
Cancer Res; 2006 Mar; 66(6):3197-204. PubMed ID: 16540671
[TBL] [Abstract][Full Text] [Related]
12. Small molecule-based chemotherapeutic approach in p16-positive and -negative HNSCC in vitro.
Aderhold C; Faber A; Grobschmidt GM; Chakraborty A; Bockmayer A; Umbreit C; Birk R; Stern-Straeter J; Hörmann K; Schultz JD
Anticancer Res; 2013 Dec; 33(12):5385-93. PubMed ID: 24324073
[TBL] [Abstract][Full Text] [Related]
13. Targeted Treatment of HPV16-positive and -negative SCC Cells With Small Molecule Tyrosine Kinase Inhibitors and Everolimus Affects MMP2 and MMP14 Expression.
Huber L; Birk R; Knuettel M; Rotter N; Aderhold C; Scherl C; Lammert A; Jungbauer F; Kramer B
Anticancer Res; 2022 Jul; 42(7):3403-3411. PubMed ID: 35790279
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-induced ROS promotes mitochondrial fission and cisplatin chemosensitivity via HIF-1α/Mff regulation in head and neck squamous cell carcinoma.
Wu K; Mao YY; Chen Q; Zhang B; Zhang S; Wu HJ; Li Y
Cell Oncol (Dordr); 2021 Oct; 44(5):1167-1181. PubMed ID: 34460078
[TBL] [Abstract][Full Text] [Related]
15. CC-223 inhibits human head and neck squamous cell carcinoma cell growth.
Wang JY; Jin X; Zhang X; Li XF
Biochem Biophys Res Commun; 2018 Feb; 496(4):1191-1196. PubMed ID: 29402408
[TBL] [Abstract][Full Text] [Related]
16. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
Ku BM; Yi SY; Koh J; Bae YH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Oncotarget; 2016 Mar; 7(12):14803-13. PubMed ID: 26909611
[TBL] [Abstract][Full Text] [Related]
17. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
Kalish LH; Kwong RA; Cole IE; Gallagher RM; Sutherland RL; Musgrove EA
Clin Cancer Res; 2004 Nov; 10(22):7764-74. PubMed ID: 15570011
[TBL] [Abstract][Full Text] [Related]
18. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.
Xie J; Li Q; Ding X; Gao Y
Cell Physiol Biochem; 2018; 46(2):676-686. PubMed ID: 29621758
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-inducible factor-1alpha polymorphisms and TSC1/2 mutations are complementary in head and neck cancers.
Hebert C; Norris K; Parashar P; Ord RA; Nikitakis NG; Sauk JJ
Mol Cancer; 2006 Jan; 5():3. PubMed ID: 16412252
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory interferon activates HIF-1α-mediated epithelial-to-mesenchymal transition via PI3K/AKT/mTOR pathway.
Yeh YH; Hsiao HF; Yeh YC; Chen TW; Li TK
J Exp Clin Cancer Res; 2018 Mar; 37(1):70. PubMed ID: 29587825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
